Ainos (AIMD) has filed complaints with NASDAQ MarketWatch and the U.S. Securities and Exchange Commission, due to concerns about unusual trading activity in its common stock, specifically large-volume sell orders. Ainos suspects that these trading activities may involve regulatory violations and urges the regulators to investigate thoroughly to uphold market fairness and protect stockholder interests. Ainos management team views this matter with the utmost seriousness, as prolonged irregular trading could pose undue risks to stockholder value. The Company has reported its concerns to regulatory bodies, calling for NASDAQ and the SEC to take action in identifying and addressing any potential illegal trading practices. Neither NASDAQ MarketWatch nor the SEC will confirm the existence of an investigation nor will they provide details on any related progress. Nevertheless, Ainos remains committed to engaging with regulators, as appropriate, to support transparency in the market and foster investor confidence.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AIMD:
- Ainos secures exclusive licensing rights for 28 patent assets
- Ainos advances innocations with AI Nose, VELDONA technologies
- Ainos receives IRB approval from National Taiwan University Hospital
- Ainos plans to initiate Taiwan clinical study of VELDONA for Sjogren’s Syndrome
- Ainos to initiate Taiwan clinical study for VELDONA in oral warts